AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition; a case mimicking AHL amyloidosis

被引:5
|
作者
Manabe, Shun [1 ,2 ,3 ]
Iwasaki, Chihiro [2 ,3 ]
Hatano, Michiyasu [2 ]
Kametani, Fuyuki [4 ]
Yazaki, Masahide [5 ]
Nitta, Kosaku [3 ]
Nagata, Michio [1 ]
机构
[1] Univ Tsukuba, Kidney & Vasc Pathol, Fac Med, 1-1-1 Tennodai, Tsukuba, Ibaraki 3058575, Japan
[2] Yokohama Rosai Hosp, Dept Nephrol, Yokohama, Kanagawa, Japan
[3] Tokyo Womens Med Univ, Dept Med, Kidney Ctr, Tokyo, Japan
[4] Tokyo Metropolitan Inst Med Sci, Dept Dementia & Higher Brain Funct, Tokyo, Japan
[5] Shinshu Univ, Inst Biomed Sci, Interdisciplinary Cluster Cutting Edge Res, Nagano, Japan
来源
BMC NEPHROLOGY | 2018年 / 19卷
基金
日本学术振兴会;
关键词
Immunoglobulin light-chain amyloidosis; Immunoglobulin heavy-and-light chain-amyloidosis; Amyloid purification; Laser microdissection; Mass spectrometry; HEAVY-CHAIN; DIAGNOSIS; FRAGMENT;
D O I
10.1186/s12882-018-1050-y
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
BackgroundImmunoglobulin heavy-and-light-chain amyloidosis (AHL amyloidosis) is a newly established disease entity where both the immunoglobulin heavy-chain and light-chain compose amyloid fibrils. The immunoglobulins responsible for the amyloid fibrils are generally identified by immunostaining and/or laser microdissection-liquid chromatography-tandem mass spectrometry (LMD-LC-MS/MS). However, both techniques do not biochemically differentiate immunoglobulins that formed amyloid fibrils from non-responsible immunoglobulins.Case presentationWe herein report a case of 67-year-old female patient with renal amyloidosis due to lymphoplasmacytic lymphoma secreting monoclonal immunoglobulin M (IgM)-kappa. Renal immunostaining monotypically positive for IgM-kappa and LMD-LC-MS/MS identification of mu heavy-chain and kappa light-chain were consistent with the diagnosis of AHL amyloidosis. In order to confirm that both the immunoglobulin heavy-chain and light-chain were forming amyloid fibrils, we performed LC-MS/MS of renal amyloid fibrils isolated by the traditional amyloid purification method. The additional LC-MS/MS identified kappa light-chain only without any heavy-chain component. These results were suggestive that amyloid fibrils were composed by kappa light-chain only and that the mu heavy-chain identified by immunostaining and LMD-LC-MS/MS was derived from the non-specific co-deposition of monoclonal IgM-kappa.ConclusionThe case was AL amyloidosis with non-amyloid forming monoclonal immunoglobulin deposition. While immunostaining and LMD-LC-MS/MS are irreplaceable techniques to classify amyloidosis, confident exclusion of the present condition should be required to diagnose AHL amyloidosis.
引用
收藏
页数:6
相关论文
共 50 条
  • [41] Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease
    Deret, S.
    Chomilier, J.
    Huang, D.-B.
    Preud'homme, J.-L.
    [J]. Protein Engineering, 10 (10):
  • [42] Use of Extended-Donor Criteria Hearts in Amyloidosis Patients Demonstrates Similar Morbidity and Mortality Compared to Non-Amyloid Recipients
    Altshuler, P. J.
    Helmers, M.
    Iyengar, A.
    Han, J.
    Rios-Diaz, A.
    Atluri, P.
    [J]. JOURNAL OF HEART AND LUNG TRANSPLANTATION, 2020, 39 (04): : S51 - S51
  • [43] Immunoglobulin Light Chain (AL) Amyloidosis Preceding Marginal Zone Lymphoma: A Case Report
    Doshi, Krishna
    Bitran, Jacob
    Adley, Brian
    Asado, Nahren
    [J]. CUREUS JOURNAL OF MEDICAL SCIENCE, 2022, 14 (07)
  • [44] Monoclonal antibodies in the treatment of AL amyloidosis: co-targetting the plasma cell clone and amyloid deposits
    Popkova, Tereza
    Hajek, Roman
    Jelinek, Tomas
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2020, 189 (02) : 228 - 238
  • [45] Systemic immunoglobulin light chain (AL) amyloidosis initially presenting as hematochezia: a case report
    Wang, Chunsaier
    Yue, Bing
    Chen, Guangyong
    Zhang, Shutian
    Luo, Xiaoya
    [J]. ANNALS OF PALLIATIVE MEDICINE, 2022, : 181 - 187
  • [46] Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report
    Yamagata, Akira
    Uchida, Takahiro
    Yamada, Yuji
    Nakanishi, Takashi
    Nagai, Kazue
    Imakiire, Toshihiko
    Oshima, Naoki
    Kumagai, Hiroo
    [J]. BMC NEPHROLOGY, 2017, 18
  • [47] Rapid clinical improvement of amyloid A amyloidosis following treatment with tocilizumab despite persisting amyloid deposition: a case report
    Akira Yamagata
    Takahiro Uchida
    Yuji Yamada
    Takashi Nakanishi
    Kazue Nagai
    Toshihiko Imakiire
    Naoki Oshima
    Hiroo Kumagai
    [J]. BMC Nephrology, 18
  • [48] Molecular modeling of immunoglobulin light chains implicates hydrophobic residues in non-amyloid light chain deposition disease
    Déret, S
    Chomilier, J
    Huang, DB
    Preud'homme, JL
    Stevens, FJ
    Aucouturier, P
    [J]. PROTEIN ENGINEERING, 1997, 10 (10): : 1191 - 1197
  • [49] Significant association between renal function and area of amyloid deposition in kidney biopsy specimens in both AA amyloidosis associated with rheumatoid arthritis and AL amyloidosis
    Kuroda, Takeshi
    Tanabe, Naohito
    Hasegawa, Eriko
    Wakamatsu, Ayako
    Nozawa, Yukiko
    Sato, Hiroe
    Nakatsue, Takeshi
    Wada, Yoko
    Ito, Yumi
    Imai, Naofumi
    Ueno, Mitsuhiro
    Nakano, Masaaki
    Narita, Ichiei
    [J]. AMYLOID-JOURNAL OF PROTEIN FOLDING DISORDERS, 2017, 24 (02): : 123 - 130
  • [50] Definition of organ involvement and treatment response in immunoglobulin light chain amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis
    Gertz, MA
    Comenzo, R
    Falk, RH
    Fermand, JP
    Hazenberg, BP
    Hawkins, PN
    Merlini, G
    Moreau, P
    Ronco, P
    Sanchorawala, V
    Sezer, O
    Solomon, A
    Grateau, G
    [J]. AMERICAN JOURNAL OF HEMATOLOGY, 2005, 79 (04) : 319 - 328